Nadexam (Indapamide, Amlodipine Besilate)

Indapamide promotes the excretion of sodium and water by inhibiting reabsorption in the kidney’s distal tubule, which reduces plasma volume. Amlodipine blocks L‑type calcium channels in arterial smooth muscle, causing vasodilation. Together they lower both cardiac output and peripheral resistance, resulting in an overall drop in arterial pressure.

The specific dose of Nadexam is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal function and other medical factors. Dosage adjustments are made to achieve optimal control while minimizing side effects.

Safety data for Nadexam in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Nadexam product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with single‑agent diuretics or calcium‑channel blockers, Nadexam offers dual mechanisms in one tablet, which can improve blood‑pressure control and simplify regimens. It may be preferred when monotherapy fails to reach targets, but clinicians consider patient‑specific factors such as renal function, electrolyte balance and drug‑interaction potential.

Store Nadexam at ambient temperature, below 25 °C, in the original blister or bottle. Keep the product away from moisture, heat and direct sunlight. Do not use if the packaging is damaged or the tablets appear discoloured.

Nadexam is taken orally, usually once daily, with or without food. Swallow the tablet whole with a full glass of water. Patients should follow the dosing schedule prescribed by their clinician and not alter the timing without medical advice.

Serious adverse events include severe hypotension, electrolyte disturbances (especially low potassium), acute kidney injury, angioedema, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden weakness, or a rash that spreads.

Nadexam is contraindicated in patients with known hypersensitivity to indapamide, amlodipine, or any component of the formulation. It should also be avoided in individuals with severe hepatic impairment, uncorrected electrolyte abnormalities, or those taking prohibited medications that may cause dangerous interactions.